Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines

Kostopoulou,Ourania  N.; Holzhauser,Stefan; Lange,Birthe  K.A.; Ohmayer,Anna; Andonova,Teodora; Bersani,Cinzia; Wickström,Malin; Dalianis,Tina

doi:10.3892/ijo.2019.4896

Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines

Authors:
- Ourania N. Kostopoulou
- Stefan Holzhauser
- Birthe K.A. Lange
- Anna Ohmayer
- Teodora Andonova
- Cinzia Bersani
- Malin Wickström
- Tina Dalianis
View Affiliations

Affiliations: Department of Oncology‑Pathology, Karolinska Institutet, 171 74 Stockholm, Sweden, Department of Women's and Children's Health, Karolinska Institutet, 171 74 Stockholm, Sweden
Published online on: October 7, 2019 https://doi.org/10.3892/ijo.2019.4896
Pages: 1372-1384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor receptor (FGFR)3 and phosphatidylinositol‑4,5‑bisphosphate 3‑kinase, catalytic subunit alpha (PIK3CA) mutations are found in various types of cancer, such as urinary bladder cancer, human papillomavirus‑positive tonsillar and base of the tongue squamous cell carcinoma, breast cancer and some childhood sarcomas. Several drugs can target these genes, some of which have been used for the treatment of urinary bladder cancer. Much less is known about childhood cancer. For this reason, the present study investigated the presence of such mutations in neuroblastomas (NBs) and tested NB cell lines for sensitivity to FGFR and phosphoinositide 3‑kinase (PI3K) inhibitors. In total, 29 NBs were examined for the presence of the three most common FGFR3 and PIK3CA mutations using a competitive allele‑specific TaqMan PCR (CAST‑PCR). Furthermore, the SK‑N‑AS, SK‑N‑BE(2)‑C, SK‑N‑DZ, SK‑N‑FI and SK‑N‑SH NB cell lines (where SK‑N‑DZ had a deletion of PIK3C2G, none had FGFR mutations according to the Cancer Program's Dependency Map, but some were chemoresistant), were tested for sensitivity to FGFR (AZD4547) and PI3K (BEZ235 and BKM120) inhibitors by viability, cytotoxicity, apoptosis and proliferation assays. CAST‑PCR detected one FGFR3 mutation in 1/29 NBs. Following treatment with FGFR and PI3K inhibitors, a decrease in viability and proliferation was observed in the majority, but not all, the cell lines. Following combination treatment with both drugs, the sensitivity of all cell lines was increased. On the whole, the findings of this study demonstrate that FGFR3 and PIK3CA mutations are uncommon in patients with NB. However, certain NB cell lines are rather sensitive to both FGFR and PI3K inhibitors alone, and even more so when the different drugs are used in combination.

View Figures

View References

1	Wesche J, Haglund K and Haugsten EM: Fibroblast growth factors and their receptors in cancer. Biochem J. 437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
2	Parker BC, Engels M, Annala M and Zhang W: Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 232:4–15. 2014. View Article : Google Scholar : PubMed/NCBI
3	Testa U, Castelli G and Pelosi E: Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel). 10:E2482018. View Article : Google Scholar
4	Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, et al: Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 13:1382–1389. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bersani C, Sivars L, Haeggblom L, DiLorenzo S, Mints M, Ahrlund-Richter A, Tertipis N, Munck-Wikland E, Näsman A, Ramqvist T and Dalianis T: Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3. Oncotarget. 8:35339–35350. 2017. View Article : Google Scholar : PubMed/NCBI
6	Taylor JG VI, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, et al: Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 119:3395–3407. 2009.PubMed/NCBI
7	Lehtinen B, Raita A, Kesseli J, Annala M, Nordfors K, Yli-Harja O, Zhang W, Visakorpi T, Nykter M, Haapasalo H and Granberg KJ: Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 17:3102017. View Article : Google Scholar : PubMed/NCBI
8	Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, et al: The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 123:855–865. 2013.PubMed/NCBI
9	Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, et al: Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in ewing sarcoma. Clin Cancer Res. 21:4935–4946. 2015. View Article : Google Scholar : PubMed/NCBI
10	Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, et al: PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 4:709–714. 2006. View Article : Google Scholar : PubMed/NCBI
11	Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L and Kieran MW: Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 58:489–491. 2012. View Article : Google Scholar
12	Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG and Ladanyi M: Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 18:748–757. 2012. View Article : Google Scholar :
13	Dam V, Morgan BT, Mazanek P and Hogarty MD: Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer. 6:1772006. View Article : Google Scholar : PubMed/NCBI
14	Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T and Limon J: EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol. 48:238–245. 2010.
15	Opel D, Poremba C, Simon T, Debatin KM and Fulda S: Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 67:735–745. 2007. View Article : Google Scholar : PubMed/NCBI
16	Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, et al: Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget. 7:57525–57544. 2016. View Article : Google Scholar : PubMed/NCBI
17	Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D and Weiss WA: Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI
18	Segerström L, Baryawno N, Sveinbjörnsson B, Wickström M, Elfman L, Kogner P and Johnsen JI: Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuro-blastoma growth in vitro and in vivo. Int J Cancer. 129:2958–2965. 2011. View Article : Google Scholar
19	Klempner SJ, Myers AP and Cantley LC: What a tangled web we weave: Emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 3:1345–1354. 2013. View Article : Google Scholar : PubMed/NCBI
20	Maris JM: Recent advances in neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
21	Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003. View Article : Google Scholar : PubMed/NCBI
22	Giraud G, Ramqvist T, Pastrana DV, Pavot V, Lindau C, Kogner P, Orrego A, Buck CB, Allander T, Holm S, et al: DNA from KI, WU and Merkel cell polyomaviruses is not detected in childhood central nervous system tumours or neuroblastomas. PLoS One. 4:e82392009. View Article : Google Scholar : PubMed/NCBI
23	Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer H, et al: Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis. 4:e5862013. View Article : Google Scholar : PubMed/NCBI
24	Biedler JL, Helson L and Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:2643–2652. 1973.PubMed/NCBI
25	Biedler JL and Spengler BA: A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chines hamster cell lives in culture. J Natl Cancer Inst. 57:683–695. 1976. View Article : Google Scholar : PubMed/NCBI
26	Sugimoto T, Tatsumi E, Kemshead JT, Helson L, Green AA and Minowada J: Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst. 73:51–57. 1984.PubMed/NCBI
27	Helson L and Helson C: Human neuroblastoma cells and 13-cis-retinoic acid. J Neurooncol. 3:39–41. 1985.PubMed/NCBI
28	LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB and Biedler JL: Multidrug resistance in human neuroblastoma cells. J Pediatr Surg. 26:1107–1112. 1991. View Article : Google Scholar : PubMed/NCBI
29	Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P and Martinsson T: High-risk neuro-blastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA. 107:4323–4328. 2010. View Article : Google Scholar
30	Kryh H, Carén H, Erichsen J, Sjöberg RM, Abrahamsson J, Kogner P and Martinsson T: Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics. 12:4432011. View Article : Google Scholar : PubMed/NCBI
31	Helson C, Zahn Z and Helson L: Reversion of p-glycoprotein mediated multidrug-resistance to vincristine and adriamycin by psc-833, a cyclosporine derivative in human neuroblastoma cell-lines. Int J Oncol. 5:1037–1042. 1994.PubMed/NCBI
32	Bersani C, Haeggblom H, Ursu RG, Giusca SE, Marklund L, Ramqvist T, Näsman A and Dalianis T: Overexpression of FGFR3 in HPV-positive tonsillar and base of tongue cancer is correlated to outcome. Anticancer Res. 38:4683–4690. 2018. View Article : Google Scholar : PubMed/NCBI
33	Holzhauser S, Kostopoulou ON, Ohmayer A, Lange BKA, Ramqvist T, Andonova T, Bersani C, Wickström M and Dalianis T: Antitumor effects in vitro of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer. Oncol Lett. In press.
34	Foucquier J and Guedj M: Analysis of drug combinations: Current methodological landscape. Pharmacol Res Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
35	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
36	Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV, et al: Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget. 7:24252–24268. 2016. View Article : Google Scholar : PubMed/NCBI
37	Arenas MA, Del Pino M and Fano V: FGFR3-related hypochondroplasia: Longitudinal growth in 57 children with the p. Asn540Lys mutation. J Pediatr Endocrinol Metab. 31:1279–1284. 2018.PubMed/NCBI
38	Chen J, Yang J, Zhao S, Ying H, Li G and Xu C: Identification of a novel mutation in the FGFR3 gene in a Chinese family with Hypochondroplasia. Gene. 641:355–360. 2018. View Article : Google Scholar
39	Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R and van der Heijden MS: A functional genetic screen identifies the phosphinositide 3-kinase pathway as a determinant of resistance to fibroblast grown factor receptor inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol. 71:858–862. 2017. View Article : Google Scholar : PubMed/NCBI
40	Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 34:2167–2177. 2015. View Article : Google Scholar
41	Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A and Turner NC: Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 3:1058–1071. 2013. View Article : Google Scholar : PubMed/NCBI
42	Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter UDA: Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
43	Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC. Cancer Res. 75:4398–4406. 2015. View Article : Google Scholar : PubMed/NCBI
44	Cai W, Song B and Ai H: Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer. Am J Transl Res. 11:1616–1625. 2019.PubMed/NCBI
45	Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, et al: First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res. 22:1932–1939. 2016. View Article : Google Scholar
46	Tamura R, Yoshihara K, Saito T, Ishimura R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda K, et al: Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 7:42018. View Article : Google Scholar : PubMed/NCBI
47	Zheng X, Naiditch J, Czurylo M, Jie C, Lautz T, Clark S, Jafari N, Qiu Y, Chu F and Madonna MB: Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics. Cell Death Dis. 4:e7402013. View Article : Google Scholar : PubMed/NCBI